Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts

The present disclosure relates to a method of treating or preventing a disease or disorder selected from the group consisting of a central nervous system disorder, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, a chronic granulomatous disorder, a polycystic ovary syndrome, a thyroid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MARTINELL PEDEMONTE Marc, TRAVER LOPEZ Estefania, GARCIA COLLAZO Ana Maria, PEREZ DE LA CRUZ MORENO Maria Angeles, PIZCUETA LALANZA Maria Pilar
Format: Patent
Sprache:eng ; heb
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator MARTINELL PEDEMONTE Marc
TRAVER LOPEZ Estefania
GARCIA COLLAZO Ana Maria
PEREZ DE LA CRUZ MORENO Maria Angeles
PIZCUETA LALANZA Maria Pilar
description The present disclosure relates to a method of treating or preventing a disease or disorder selected from the group consisting of a central nervous system disorder, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, a chronic granulomatous disorder, a polycystic ovary syndrome, a thyroid carcinoma, a thyroid autoimmune disorder, a pituitary adenoma, atherosclerosis, hypertension, a skin disease, an inflammation and autoimmune disease, an inflammatory respiratory disease, and a mitochondrial disease by administering 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of a mitochondrial disease.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_IL279186A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IL279186A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_IL279186A3</originalsourceid><addsrcrecordid>eNrjZIgNLU5VyE9TMNWNjjbRjTbSjTbVTUxOLanMKagsykzJzNM10q3MiU0tycivqIxNSs2rAvJ0DXWMdUsyMhOr8nNAalJ1jXRMdFMy8_NSFRLzUhQyS4oVihNzSop5GFjTEnOKU3mhNDeDnJtriLOHbmpBfnxqcQHQprzUknhPHyNzS0MLM0djggoAMis4iw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts</title><source>esp@cenet</source><creator>MARTINELL PEDEMONTE Marc ; TRAVER LOPEZ Estefania ; GARCIA COLLAZO Ana Maria ; PEREZ DE LA CRUZ MORENO Maria Angeles ; PIZCUETA LALANZA Maria Pilar</creator><creatorcontrib>MARTINELL PEDEMONTE Marc ; TRAVER LOPEZ Estefania ; GARCIA COLLAZO Ana Maria ; PEREZ DE LA CRUZ MORENO Maria Angeles ; PIZCUETA LALANZA Maria Pilar</creatorcontrib><description>The present disclosure relates to a method of treating or preventing a disease or disorder selected from the group consisting of a central nervous system disorder, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, a chronic granulomatous disorder, a polycystic ovary syndrome, a thyroid carcinoma, a thyroid autoimmune disorder, a pituitary adenoma, atherosclerosis, hypertension, a skin disease, an inflammation and autoimmune disease, an inflammatory respiratory disease, and a mitochondrial disease by administering 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of a mitochondrial disease.</description><language>eng ; heb</language><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210131&amp;DB=EPODOC&amp;CC=IL&amp;NR=279186A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210131&amp;DB=EPODOC&amp;CC=IL&amp;NR=279186A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MARTINELL PEDEMONTE Marc</creatorcontrib><creatorcontrib>TRAVER LOPEZ Estefania</creatorcontrib><creatorcontrib>GARCIA COLLAZO Ana Maria</creatorcontrib><creatorcontrib>PEREZ DE LA CRUZ MORENO Maria Angeles</creatorcontrib><creatorcontrib>PIZCUETA LALANZA Maria Pilar</creatorcontrib><title>Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts</title><description>The present disclosure relates to a method of treating or preventing a disease or disorder selected from the group consisting of a central nervous system disorder, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, a chronic granulomatous disorder, a polycystic ovary syndrome, a thyroid carcinoma, a thyroid autoimmune disorder, a pituitary adenoma, atherosclerosis, hypertension, a skin disease, an inflammation and autoimmune disease, an inflammatory respiratory disease, and a mitochondrial disease by administering 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of a mitochondrial disease.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZIgNLU5VyE9TMNWNjjbRjTbSjTbVTUxOLanMKagsykzJzNM10q3MiU0tycivqIxNSs2rAvJ0DXWMdUsyMhOr8nNAalJ1jXRMdFMy8_NSFRLzUhQyS4oVihNzSop5GFjTEnOKU3mhNDeDnJtriLOHbmpBfnxqcQHQprzUknhPHyNzS0MLM0djggoAMis4iw</recordid><startdate>20210131</startdate><enddate>20210131</enddate><creator>MARTINELL PEDEMONTE Marc</creator><creator>TRAVER LOPEZ Estefania</creator><creator>GARCIA COLLAZO Ana Maria</creator><creator>PEREZ DE LA CRUZ MORENO Maria Angeles</creator><creator>PIZCUETA LALANZA Maria Pilar</creator><scope>EVB</scope></search><sort><creationdate>20210131</creationdate><title>Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts</title><author>MARTINELL PEDEMONTE Marc ; TRAVER LOPEZ Estefania ; GARCIA COLLAZO Ana Maria ; PEREZ DE LA CRUZ MORENO Maria Angeles ; PIZCUETA LALANZA Maria Pilar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_IL279186A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; heb</language><creationdate>2021</creationdate><toplevel>online_resources</toplevel><creatorcontrib>MARTINELL PEDEMONTE Marc</creatorcontrib><creatorcontrib>TRAVER LOPEZ Estefania</creatorcontrib><creatorcontrib>GARCIA COLLAZO Ana Maria</creatorcontrib><creatorcontrib>PEREZ DE LA CRUZ MORENO Maria Angeles</creatorcontrib><creatorcontrib>PIZCUETA LALANZA Maria Pilar</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MARTINELL PEDEMONTE Marc</au><au>TRAVER LOPEZ Estefania</au><au>GARCIA COLLAZO Ana Maria</au><au>PEREZ DE LA CRUZ MORENO Maria Angeles</au><au>PIZCUETA LALANZA Maria Pilar</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts</title><date>2021-01-31</date><risdate>2021</risdate><abstract>The present disclosure relates to a method of treating or preventing a disease or disorder selected from the group consisting of a central nervous system disorder, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, a chronic granulomatous disorder, a polycystic ovary syndrome, a thyroid carcinoma, a thyroid autoimmune disorder, a pituitary adenoma, atherosclerosis, hypertension, a skin disease, an inflammation and autoimmune disease, an inflammatory respiratory disease, and a mitochondrial disease by administering 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of a mitochondrial disease.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; heb
recordid cdi_epo_espacenet_IL279186A
source esp@cenet
title Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A23%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MARTINELL%20PEDEMONTE%20Marc&rft.date=2021-01-31&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EIL279186A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true